Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib.

Exclusion Criteria

• •1. Patients unable to tolerate Sunitinib/BIBF 1120 treatment
• •2. Treatment with other investigational drugs or participation in another clinical study within the past 4 weeks before start of therapy or concomitantly with this study.
• •3. Patients unable to comply with the 1199.26 protocol.
• •4. Pregnancy or breast feeding.
• •5. Active alcohol or drug abuse.
• •6. Women of child bearing potential, or men who are able to father a child, unwilling to use a medically acceptable form of contraception during the study period.